Literature DB >> 12096910

Crystal structure of the Ly49I natural killer cell receptor reveals variability in dimerization mode within the Ly49 family.

Nazzareno Dimasi1, Mark W Sawicki, Lora A Reineck, Yili Li, Kannan Natarajan, David H Margulies, Roy A Mariuzza.   

Abstract

Natural killer (NK) cells play a crucial role in the detection and destruction of virally infected and tumor cells during innate immune responses. The cytolytic activity of NK cells is regulated through a balance of inhibitory and stimulatory signals delivered by NK receptors that recognize classical major histocompatabilty complex class I (MHC-I) molecules, or MHC-I homologs such as MICA, on target cells. The Ly49 family of NK receptors (Ly49A through W), which includes both inhibitory and activating receptors, are homodimeric type II transmembrane glycoproteins, with each subunit composed of a C-type lectin-like domain tethered to the membrane by a stalk region. We have determined the crystal structure, at 3.0 A resolution, of the murine inhibitory NK receptor Ly49I. The Ly49I monomer adopts a fold similar to that of other C-type lectin-like NK receptors, including Ly49A, NKG2D and CD69. However, the Ly49I monomers associate in a manner distinct from that of these other NK receptors, forming a more open dimer. As a result, the putative MHC-binding surfaces of the Ly49I dimer are spatially more distant than the corresponding surfaces of Ly49A or NKG2D. These structural differences probably reflect the fundamentally different ways in which Ly49 and NKG2D receptors recognize their respective ligands: whereas the single MICA binding site of NKG2D is formed by the precise juxtaposition of two monomers, each Ly49 monomer contains an independent binding site for MHC-I. Hence, the structural constraints on dimerization geometry may be relatively relaxed within the Ly49 family. Such variability may enable certain Ly49 receptors, like Ly49I, to bind MHC-I molecules bivalently, thereby stabilizing receptor-ligand interactions and enhancing signal transmission to the NK cell. (c) 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12096910     DOI: 10.1016/s0022-2836(02)00498-9

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  7 in total

Review 1.  Structure of the Ly49 family of natural killer (NK) cell receptors and their interaction with MHC class I molecules.

Authors:  Nazzareno Dimasi; Lorenzo Moretta; Roberto Biassoni
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 2.  Structural basis for recognition of MHC and MHC-like ligands by natural killer cell receptors.

Authors:  Lu Deng; Roy A Mariuzza
Journal:  Semin Immunol       Date:  2006-06       Impact factor: 11.130

3.  Expression, refolding and crystallizations of the Grb2-like (GADS) C-terminal SH3 domain complexed with a SLP-76 motif peptide.

Authors:  Alessandro Faravelli; Nazzareno Dimasi
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-12-16

4.  A positive cooperativity binding model between Ly49 natural killer cell receptors and the viral immunoevasin m157: kinetic and thermodynamic studies.

Authors:  Pablo N Romasanta; Lucrecia M Curto; Nicolas Urtasun; María B Sarratea; Santiago Chiappini; María V Miranda; José M Delfino; Roy A Mariuzza; Marisa M Fernández; Emilio L Malchiodi
Journal:  J Biol Chem       Date:  2013-12-30       Impact factor: 5.157

Review 5.  The balancing act: inhibitory Ly49 regulate NKG2D-mediated NK cell functions.

Authors:  Subramaniam Malarkannan
Journal:  Semin Immunol       Date:  2006-06       Impact factor: 11.130

6.  High allelic polymorphism, moderate sequence diversity and diversifying selection for B-NK but not B-lec, the pair of lectin-like receptor genes in the chicken MHC.

Authors:  Sally L Rogers; Jim Kaufman
Journal:  Immunogenetics       Date:  2008-06-24       Impact factor: 2.846

Review 7.  Structural basis for recognition of cellular and viral ligands by NK cell receptors.

Authors:  Yili Li; Roy A Mariuzza
Journal:  Front Immunol       Date:  2014-03-26       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.